ONX 0912 is an orally bioavailable proteasome inhibitor.
1 It potently targets the chymotrypsin-like activity of the 20S proteasome subunits β5 and LMP7 (IC
50s = 36 and 82 nM, respectively).
1 ONX 0912 inhibits the growth of multiple myeloma cells at nanomolar concentrations while not decreasing the viability of normal peripheral blood mononuclear cells at 1 μM.
2 It blocks the growth of xenografted human multiple myeloma cells in mice when given orally.
2 ONX 0912 has potential applications in certain types of cancer as well as other diseases that require proteasome activity.
3,4,5,6